The JAVELIN RENAL 101 trial investigated axitinib with avelumab against sunitinib, displaying advantageous median PFS (13.8 vs. 7.0 months, HR 0.62, p < 0.001), but lacking proof of a subsequent OS benefit (HR 0.83, p = 0.13) for PD-L1 positive tumours [36]. The gene discussed is CD274; the disease is neoplasm.